Page last updated: 2024-10-24

positive regulation of L-glutamate import across plasma membrane

Definition

Target type: biologicalprocess

Any process that activates or increases the frequency, rate or extent of L-glutamate import into a cell. [GOC:TermGenie]

Positive regulation of L-glutamate import across the plasma membrane is a complex process involving a series of molecular events that ultimately control the uptake of glutamate, a key excitatory neurotransmitter, into cells. This process is essential for neuronal communication and plays a crucial role in synaptic plasticity, learning, and memory.

Here's a detailed breakdown of the biological process:

1. **Glutamate Transporter Expression and Localization:** The process begins with the expression of glutamate transporters, specifically members of the excitatory amino acid transporter (EAAT) family, on the plasma membrane of neurons and glial cells. These transporters are responsible for mediating the influx of glutamate across the membrane.

2. **Signal Transduction Pathways:** The regulation of glutamate transporter activity is influenced by a variety of signal transduction pathways, including those triggered by neurotransmitters, growth factors, and other signaling molecules. These pathways can modulate transporter expression, trafficking, and activity.

3. **Transporter Conformational Changes:** Upon binding to glutamate, the transporter undergoes conformational changes that allow the neurotransmitter to move across the membrane. This movement is driven by an electrochemical gradient and is coupled to the co-transport of sodium ions (Na+) and protons (H+) or the counter-transport of potassium ions (K+).

4. **Regulation by Membrane Potential:** The membrane potential of the cell also plays a role in regulating glutamate uptake. A more negative membrane potential enhances transporter activity, while a more positive membrane potential reduces it.

5. **Regulation by Intracellular Glutamate Levels:** The concentration of glutamate within the cell can also regulate its uptake. When intracellular glutamate levels are high, the transporter activity can be downregulated to prevent excessive accumulation.

6. **Regulation by Cytoskeletal Dynamics:** The cytoskeleton plays a role in anchoring and trafficking of glutamate transporters to the plasma membrane. Modifications in the cytoskeleton can influence transporter localization and thus affect glutamate uptake.

7. **Regulation by Post-translational Modifications:** Glutamate transporters are subject to post-translational modifications, such as phosphorylation, glycosylation, and ubiquitination, which can alter their activity and stability.

8. **Regulation by Interaction with Other Proteins:** Glutamate transporters can interact with other proteins, including scaffolding proteins, kinases, and phosphatases, which can modulate their function and contribute to the overall regulation of glutamate import.

Overall, the regulation of L-glutamate import across the plasma membrane is a highly regulated process that involves the coordinated action of multiple molecular players. This precise regulation ensures proper glutamate homeostasis, which is crucial for maintaining neuronal function and preventing excitotoxicity, a harmful condition that can lead to neuronal damage and death.'
"

Proteins (1)

ProteinDefinitionTaxonomy
Presenilin-1A presenilin-1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P49768]Homo sapiens (human)

Compounds (22)

CompoundDefinitionClassesRoles
tocopheroxy radicaltocopheroxy radical: RN given refers to radical ion (1+), (2R-(2R*(4R*,8R*)))-isomer; RN for cpd without isomeric designation not available 12/90tocopherol
7-amino-4-chloro-3-methoxy-2-benzopyran-1-oneisocoumarins
tarenflurbiltarenflurbil: R-enantiomer of flurbiprofen but not a COX inhibitor; modulates NF-kB, gamma-secretase, amyloid beta-protein;flurbiprofen
cholanic acid5beta-cholanic acids;
cholanic acid
t0901317T0901317: an LXRalpha and LXRbeta agonist
n-(n-(3,5-difluorophenacetyl)alanyl)phenylglycine tert-butyl esterDAPT : A dipeptide consisting of alanylphenylglycine derivatised as a 3,5-difluorophenylacetamide at the amino terminal and a tert-butyl ester at the carboxy terminal. A gamma-secretase inhibitor.carboxylic ester;
difluorobenzene;
dipeptide;
tert-butyl ester
EC 3.4.23.46 (memapsin 2) inhibitor
sulindac sulfidesulindac sulfide : An aryl sulfide that is a metabolite of sulindac. A non-steroidal anti-inflammatory drug, which also has anticancer activity.

sulindac sulfide: sulfated analog of indomethacin & inhibitor of prostaglandin synthesis in vitro; RN given refers to cpd without isomeric designation; structure given in first source
aryl sulfide;
monocarboxylic acid;
organofluorine compound
antineoplastic agent;
apoptosis inducer;
non-steroidal anti-inflammatory drug
l 685458L 685458: a gamma-secretase inhibitor; structure in first source

L-685,458 : A peptide and carboxamide that is L-leucyl-L-phenylalaninamide, L-Leu-L-Phe-NH2, which has been acylated on the N-terminus by a Phe-Phe hydroxyethylene dipeptide isotere, 2R-benzyl-5S-tert-butoxycarbonylamino-4R-hydroxy-6-phenylhexanoic acid. Compounds based on the structure of L-685,458 are potent inhibitors of gamma-secretase, which mediates the final catalytic step that generates the amyloid beta-peptide (Abeta), which assembles into the neurotoxic aggregates in the brains of sufferers of Alzheimer's disease.
carbamate ester;
monocarboxylic acid amide;
peptide;
secondary alcohol
EC 3.4.23.46 (memapsin 2) inhibitor;
peptidomimetic
mk 0752
ly 450139peptide
chf 50741-(3',4'-dichloro-2-fluoro(1,1'-biphenyl)-4-yl)cyclopropanecarboxylic acid: a beta-amyloid(1-42) lowering agent; structure in first source
ly 411575dibenzoazepine;
difluorobenzene;
lactam;
secondary alcohol
EC 3.4.23.46 (memapsin 2) inhibitor
4-(2-((1r)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acidsulfonamide
begacestat
e 2012
mrk 560MRK 560: a gamma-secretase inhibitor; MRK-560 is the (cis)-isomer; structure in first source
1, 3-di-(n-carboxybenzoyl-leucyl-leucyl)amino acetone1, 3-di-(N-carboxybenzoyl-leucyl-leucyl)amino acetone: structure in first source
pf 3084014nirogacestat : A member of the class of imidazoles that is 1H-imidazole substituted by a 1-[(2,2-dimethylpropyl)amino]-2-methylpropan-2-yl group at position 1 and a {N-[(2S)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl]-L-norvalyl}amino group at position 4. It is a gamma-secretase inhibitor whose hydrobromide salt is indicated for adult patients with progressing desmoid tumours who require systemic treatment.

nirogacestat: an antineoplastic agent
bms 708163BMS 708163: structure in first sourceoxadiazole;
ring assembly
ro 4929097dibenzoazepine;
dicarboxylic acid diamide;
lactam;
organofluorine compound
EC 3.4.23.46 (memapsin 2) inhibitor
jnj 40418677
(r)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1h-pyrazolo(4,3-c)quinoline(R)-4-cyclopropyl-7,8-difluoro-5-(4-(trifluoromethyl)phenylsulfonyl)-4,5-dihydro-1H-pyrazolo(4,3-c)quinoline: gamma secretase inhibitor; structure in first source